Cochrane Database Syst Rev · 2009 · Meta-analysis / systematic review
Benzodiazepines for deliriumConclusion: No adequately controlled trials could be found to support the use of benzodiazepines in the treatment of non-alcohol withdrawal related delirium among hospitalised patients, and at this time benzodiazepines cannot be recommended for the control of this condition. Because of the scarcity of trials with randomization of patients, placebo control, and adequate concealment of allocation of subjects, it is clear that further research is required to determine the role of benzodiazepines in the treatment of non-alcohol withdrawal related delirium.
PubMed 19160280 ↗Cochrane Database Syst Rev · 2009 · Meta-analysis / systematic review
Benzodiazepines for deliriumConclusion: No adequately controlled trials could be found to support the use of benzodiazepines in the treatment of non-alcohol withdrawal related delirium among hospitalised patients, and at this time benzodiazepines cannot be recommended for the control of this condition. Because of the scarcity of trials with randomization of patients, placebo control, and adequate concealment of allocation of subjects, it is clear that further research is required to determine the role of benzodiazepines in the treatment of non-alcohol withdrawal related delirium.
PubMed 19821364 ↗Cochrane Database Syst Rev · 2012 · Meta-analysis / systematic review
Muscle relaxants for pain management in rheumatoid arthritisConclusion: Based upon the currently available evidence in patients with RA, benzodiazepines (diazepam and triazolam) do not appear to be beneficial in improving pain over 24 hours or one week. The non-benzodiazepine agent zopiclone also did not significantly reduce pain over two weeks. However, even short term muscle relaxant use (24 hours to 2 weeks) is associated with significant adverse events, predominantly drowsiness and dizziness.
PubMed 22258993 ↗Cochrane Database Syst Rev · 2015 · Meta-analysis / systematic review
Haloperidol for the treatment of nausea and vomiting in palliative care patientsConclusion: Since the last version of this review, we found one new study for inclusion but the conclusion remains unchanged. There is incomplete evidence from published RCTs to determine the effectiveness of haloperidol for nausea and vomiting in palliative care. Other than the trial of ABH gel vs placebo, we did not identify any fully published RCTs exploring the effectiveness of haloperidol for nausea and vomiting in palliative care patients for this update, but two trials are underway.
PubMed 26524474 ↗Health Technol Assess · 2016 · Meta-analysis / systematic review
Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic reviewPubMed 27035758 ↗